Aristotle University Of Thessaloniki (AUTH)
Φαρμακοχημική προσέγγιση στην αντιμετώπιση χρόνιων παθήσεων: βιοϊσοστέρης σχεδιασμός, σύνθεση, in vitro και in silico μελέτη
Abstract
dc:descriptionAldose reductase enzyme (ALR2) of the polyol metabolic pathway, and especially its inhibition by aldose reductase inhibitors (ARIs), has been gaining attention over the last years from the pharmaceutical community, as it appears to be a promising pharmacotherapeutic target. Ιτ was first found to be implicated in the etiology of the long term diabetic complications. However, to date, emerging reports have suggested that it can be involved also in numerous chronic pathological processes that have become major threats to human health. Over the last decades, a number of promising ARIs have been developed but only Epalrestat has made it to the market in Japan. All the other compounds that have reached the stage of clinical trials on humans have been withdrawn due to their inadequate pharmacokinetic profile or side effects. Thus, it is becoming of great importance, novel chemotypes to be developed, lacking the poor pharmacokinetic profile or the side-effects of the various ARIs that have failed to the clinical trials. The present PhD thesis involves the pharmakochemical study of novel ARIs. The design was based on the concept of bioisosterism, a strategy used for molecular modifications on the lead compound. 2-(phenylsulfonamido)acetic acid was chosen as the lead compound and a series of non classical isosters to the acetic acid moiety were used for the latter’s replacement. Diverse functional groups are known for their isosteric relationships with the carboxylate group, such as 2,6-difluorophenol, methylsulfonylamine, tetrazole and cycloserine. The in vitro data revealed important bioisosterism in the case of the difluorophenol and a series of derivatives with various chemical modifications, such as introduction of 4-bromo-2-fluoro-methylobenzene moiety as a potent “privileged scaffold”, was developed. Important bioisosterism was shown also in the case of L-cycloserine but not D-cycloserine derivatives. All the synthesized compounds were tested in vitro for their ability to inhibit the enzymes ALR2 and ALR1. Furthermore their antioxidant potential was tested in two different in vitro systems: the homogeneous system of DPPH and the heterogeneous system of DOPC liposomes. The in silico studies involved 2D-QSAR and establishment of a neural network heuristic predictor model for ARIs. The experimental data derived from the in vitro studies of this thesis were used for the model’s predictive ability evaluation.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Alexiou, Polyxeni
- Αλεξίου, Πολυξένη
Subjects
dc:subject × 20- Ένζυμο αναγωγάση της αλδόζης
- Αναστολείς της αναγωγάσης της αλδόζης
- Ένζυμο αναγωγάση των αλδεϋδών
- Αντιοξειδωτικό δυναμικό
- Ελεύθερη ρίζα DPPH
- Dopc λιποσώματα
- Χρόνιες παθολογικές καταστάσεις
- In silico μελέτη, νευρωνικά δίκτυα
- Aldose reductase enzyme (ALR2)
- Aldose reductase inhibitors (ARIs)
- Aldehyde reductase (ALR1)
- Antioxidant potential
- Free radical DPPH
- Dopc liposomes
- Chronic pathologies
- In silico studies, neural networks (NNs)
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27464